Zimmer Biomet (ZBH)
NYSEHealth CareMedical DevicesSnapshot 2026-07-08
$87.56-2.07%
Close 2026-07-08 · 1-day change
Reading ZBH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ZBH free→NYSEHealth CareMedical DevicesSnapshot 2026-07-08
Reading ZBH? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ZBH free→QuarterlyIQ Insights · ZBH
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 14 valuation methods, at three horizons. Current price $87.56. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $89 ZBH trades at 11× p/e, below its 37× p/e peer median. Our $119 fair value sits well above the price. We hold it with low confidence: our number sits above the analyst range and the peer anchor overstates how cheap it looks. Analysts target $83–$105. Note: our $119 fair value sits above the entire analyst range ($83–$105). Not investment advice.
$83.00 – $105.00 (median $92.00) · 5 analysts · as of 2026-04-29
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $8.61/sh owner earnings.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $93.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $124.41 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $115.80 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $17.60 | — | — | TTM | high |
| graham number | 12M | $111.17 | — | — | TTM | high |
| Mgmt guidance | 12M | $303.98 | 35.9 | 8.47 | Mgmt | high |
| Peer EV/EBITDA | 12M | $37.34 | 6.0 | 12.24 | TTM | high |
| Peer P/FCF | 12M | $153.78 | 23.6 | 6.53 | TTM | high |
| Peer P/E | 12M | $304.16 | 35.9 | 8.48 | TTM | high |
| Peer P/S | 12M | $116.45 | 2.7 | 42.95 | TTM | high |
| PEG | 12M | $74.61 | 8.8 | 8.48 | TTM | high |
| residual income | 12M | $77.53 | — | — | TTM | high |
| Own P/E history | 12M | $117.84 | 13.9 | 8.48 | TTM | high |
| triangulated | 12M | $312.31 | 35.9 | 8.71 | Triangulated | high |
| Mgmt guidance | 3Y | $342.10 | 35.9 | 9.54 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $169.93 | 23.6 | 7.22 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $339.98 | 35.9 | 9.48 | Analyst | medium |
| Peer P/S | 3Y | $129.03 | 2.7 | 47.59 | Analyst | medium |
| PEG | 3Y | $83.40 | 8.8 | 9.48 | Analyst | medium |
| Own P/E history | 3Y | $131.71 | 13.9 | 9.48 | Analyst | medium |
| Mgmt guidance | 5Y | $370.12 | 35.9 | 10.32 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $181.63 | 23.6 | 7.71 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $363.51 | 35.9 | 10.13 | Analyst | high |
| Peer P/S | 5Y | $137.96 | 2.7 | 50.88 | Analyst | high |
| PEG | 5Y | $89.17 | 8.8 | 10.13 | Analyst | high |
| Own P/E history | 5Y | $140.83 | 13.9 | 10.13 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.